Generic name: etoposide
Dosage form: Injection / Capsules
Medically reviewed on December 8, 2017.
For recommended dosing adjustments in patients with renal impairment see PRECAUTIONS section.
Chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity.
In small cell lung cancer, the recommended dose of VePesid Capsules is two times the IV dose rounded to the nearest 50 mg (i.e., two times 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days).
The dosage should be modified to take into account the myelosuppressive effects of other drugs in the combination or the effects of prior x-ray therapy or chemotherapy which may have compromised bone marrow reserve.
To minimize the risk of dermal exposure, always wear impervious gloves when handling blisterpacks of individually labeled blisters containing VePesid capsules. This includes all handling activities in clinical settings, pharmacies, storerooms, and home healthcare settings, including during unpacking and inspection, transport within a facility, and dose preparation and administration.
VePesid Capsules must be stored under refrigeration 2°– 8° C (36°– 46° F). The capsules are stable for 24 months under such refrigeration conditions.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about VePesid (etoposide)
- VePesid Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- En Español
- 0 Reviews
- Drug class: mitotic inhibitors